Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Atopic Dermatitis

An Introduction to Atopic Dermatitis

Supported by:
EU Partner
EU Partner
Mark CompleteCompleted
BookmarkBookmarked

As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Prof. Dr. med. Diamant Thaçi, Dr Benjamin Ungar

Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.

16 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

An allergist shares her expert insights and guidance on key clinical questions around the changing paradigm in the diagnosis and management of pet allergies.

8 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Guatemala, Hong Kong, Hungary, Iceland, Italy, Kuwait, Lebanon, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Singapore, South Korea, Spain, Sudan, Sweden, Taiwan, Thailand, The Netherlands, and UAE

Watch highlights of three ADVENT symposia presented at EADV 2023

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Elaine Siegfried, Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg

Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

5 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Lebanon, Macau, Malaysia, The Netherlands, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, and UAE

Key updates from 2 cutting-edge expert symposia presented at WCD 2023

Developed by Touch

Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern ...

Developed by Touch

Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children's Hospital of Chicago, Chicago, IL, ...

Developed by Touch

JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of ...

Developed by Touch

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, ...

Developed by Touch

There are numerous therapeutics available to patients with inflammatory skin diseases, including TNF-alpha inhibitors, IL inhibitors, TYK2 and JAK inhibitors, optimising the use of these therapies could be achieved with a personalised approach to treatment. We were delighted to speak ...

Developed by Touch
Coverage from: EADV

ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his analysis of these studies presented at EADV, focusing on improvement in itch severity. The abstract 'Lebrikizumab monotherapy improved itch in adults and adolescents with moderate to severe atopic dermatitis in two phase 3 trials.' (Abstract number: 765) was presented at EADV 2022, 7-10 September, 2022. Questions What is the impact of itch on quality of life in atopic dermatitis? (0:21) Could you give us a brief overview of the ADvocate 1 and ADvocate 2 studies and their primary findings? (0:38) What were the findings in terms of itch severity, and how clinically meaningful was this change? (1:26) What will be the clinical impact of these findings? (2:51) Disclosures: Gil Yosipovitch discloses consulting for Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient and Pfizer; receiving grant/ research support from Sanofi Regenron, Eli Lilly, Novartis, Pfizer, Escient; serving on advisory boards for Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient and Pfizer; receiving honoraria from Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient, Pfizer and Novartis. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Developed by Touch
Coverage from: EAACI Highlights

Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the aims, outcome measures ...

Developed by Touch
Coverage from: EAACI Highlights

Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of ...

Load More...
Close Popup